shot-button
Subscription Subscription
Home > News > World News > Article > Major cancer breakthrough

Major cancer breakthrough

Updated on: 17 February,2016 06:24 AM IST  | 
Agencies |

Tests of a potentially revolutionary cancer therapy have had “extraordinary” results on terminally ill patients, scientists have revealed

Major cancer breakthrough

Scientists describes the results as a u00c3u00a2u00c2u0080u00c2u0098potential paradigm shiftu00c3u00a2u00c2u0080u00c2u0099 in cancer treatment.

Washington D C: Tests of a potentially revolutionary cancer therapy have had “extraordinary” results on terminally ill patients, scientists have revealed. In one study, more than nine out of ten participants with a severe form of leukaemia saw their symptoms completely vanish.



Scientists describes the results as a 'potential paradigm shift' in cancer treatment. Pic/GettyImages


Four out of five patients with some other blood cancers responded positively to the treatment and more than half ended up symptom free.


Lead scientist Professor Stanley Riddell, from the Fred Hutchinson Cancer Research Center in Seattle, US, said the results were among patients who were projected to have two to five months to live. He said, “This is extraordinary. This is unprecedented in medicine to be honest, to get response rates in this range in these very advanced patients.”

The technique involves removing immune cells called T-cells from patients, tagging them with “receptor” molecules that target cancer, and putting them back into the body in an infusion. Once attached to the T-cells, they reduce the ability of the cancer to shield itself from the body’s natural immune system.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK